ClinicalTrials.gg
CompletedNCT04418765DELIVERUpdated Sep 29, 2023Results posted

A Study to Evaluate the Efficacy and Safety of Eptinezumab for the Prevention of Migraine in Participants That Are Not Helped by Previous Preventive Treatments

A Phase 3 interventional study of Eptinezumab and Placebo in Migraine, sponsored by H. Lundbeck A/S. Completed at 138 sites in 17 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-09-29.

Sponsored by H. Lundbeck A/S · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
892
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 21 studies testing eptinezumab in Migraine Disorders — 6 open to participants now, 6 under way, 5 of them phase 3. eptinezumab · Migraine Disorders.

Enrollment
4th of 21
892 · median 193
Started
2020
with 1 other
Phase 3
13 of 21
5 open now
Registered
8th of 21
by date
Lead sponsor
12 of 21
H. Lundbeck A/S

Among the 21 studies testing eptinezumab in Migraine Disorders, this one is the 4th largest by enrollment, is one of 2 that started in 2020, is one of 13 in phase 3, and was the 8th registered.

Migraine Disorders

1,658 studies on the registry are indexed under Migraine Disorders; 339 are open to participants now.

Browse Migraine Disorders studies →

Open to participants now

6 of the 21 studies testing eptinezumab in Migraine Disorders are open now, in 11 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About eptinezumab

eptinezumab: first FDA approval 2020 (VYEPTI), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies testing eptinezumab in Migraine Disorders, or all of them as a file.
02

Study summary

Evaluation of eptinezumab in the prevention of migraine in participants with unsuccessful prior preventive treatments.

Read the detailed description

The total study duration from the screening visit to the completion visit is approximately 76 weeks and includes a screening period (28-30 days), a placebo-controlled treatment period (24 weeks) and a treatment extension period (48 weeks).

The participant will start treatment at the baseline visit and follow a 12-week dosing schedule with either eptinezumab (100 or 300 milligrams [mg]) or placebo by intraveneous (IV) infusion. Participants who were assigned to placebo in the placebo-controlled treatment period, will be randomly allocated to one of two treatment groups: eptinezumab 300 mg or eptinezumab 100 mg.

03

Conditions studied

  • Migraine

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The participant has a diagnosis of migraine, with a history of chronic or episodic migraines of at least 12 months prior to the Screening Visit
  • The participant has a migraine onset of ≤50 years of age.
  • The participant has ≥4 migraine days per month for each month within the past 3 months prior to the Screening Visit.
  • The participant has demonstrated compliance with the Headache eDiary by entry of data for at least 24 of the 28 days following the Screening Visit.
  • The participant fulfils the following criteria for chronic migraine (CM) or episodic migraine (EM) in prospectively collected information in the eDiary during the screening period:
  • For participants with CM: Migraine occurring on ≥8 days and headache occurring on >14 days
  • For participants with EM: Migraine occurring on ≥4 days and headache occurring on ≤14 days
  • The participant has documented evidence of treatment failure (must be supported by medical record or by physician's confirmation specific to each treatment) in the past 10 years of 2-4 different migraine preventive medications.
  • The participant has a history of either previous or active use of triptans for migraine.

Exclusion criteria

Exclusion Criteria:

  • The participant has experienced failure on a previous treatment targeting the calcitonin gene-related peptide (CGRP) pathway.
  • The participant has a treatment failure on valproate/divalproex or botulinum toxin A/B and the treatment is not the latest preventive medication prior to study inclusion. The medication is regarded as the latest if the medication start date is after the start date of the other preventive medications and the medication stop date is after the stop date of the other preventive medications.
  • The participant has confounding and pain syndromes, (for example, fibromyalgia, chronic low back pain, complex regional pain syndrome).
  • The participant has a diagnosis of acute or active temporomandibular disorder.
  • The participant has a history or diagnosis of chronic tension-type headache, hypnic headache, cluster headache, hemicrania continua, new daily persistent headache, or unusual migraine subtypes such as hemiplegic migraine (sporadic and familial), ophthalmoplegic migraine, and migraine with neurological accompaniments that are not typical of migraine aura (diplopia, altered consciousness, or long duration).
  • The participant has a psychiatric condition that is uncontrolled and/or untreated for a minimum of 6 months prior to the Screening Visit. Participants with a lifetime history of psychosis and/or mania in the last 5 years prior to the Screening Visit are excluded.
  • The participant has a history of clinically significant cardiovascular disease or vascular ischaemia or thromboembolic events (for example, cerebrovascular accident, deep vein thrombosis, or pulmonary embolism).

Other in- and exclusion criteria may apply

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
892 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Participants will receive placebo matching to eptinezumab by IV infusion, every 12 weeks starting from Baseline (Day 0) through Week 24.

    Drug: Placebo

  • Experimental
    Eptinezumab 100 mg

    Participants will receive eptinezumab 100 mg by IV infusion, every 12 weeks starting from Baseline (Day 0) through Week 24.

    Drug: Eptinezumab

  • Experimental
    Eptinezumab 300 mg

    Participants will receive eptinezumab 300 mg by IV infusion, every 12 weeks starting from Baseline (Day 0) through Week 24.

    Drug: Eptinezumab

Interventions

  • Eptinezumab, concentrate for solution for infusion 100 mg/milliliter (mL)

  • DrugPlacebo

    concentrate for solution for infusion, intravenously

06

What researchers measure

Primary outcomes

  1. Change From Baseline in the Number of Monthly Migraine Days (MMDs) Averaged Over Weeks 1 to 12

    A migraine day was defined as any day the participant reported a headache that met criterion A, B, C, or D: Criterion A (all of the following criteria): lasted ≥4 hours, had ≥2 of the following: unilateral location; pulsating quality; moderate or severe pain intensity; aggravation by, or causing avoidance of, routine physical activity; and was accompanied by ≥1 of the following: nausea; vomiting; photophobia and phonophobia. Criterion B: lasted ≥30 minutes and the participant had an aura with the headache. Criterion C: lasted ≥30 minutes and met ≥2 of the following criteria: lasted ≥4 hours, had ≥2 of the following: unilateral location; pulsating quality; moderate or severe pain intensity; aggravation by, or causing avoidance of, routine physical activity, and was accompanied by ≥1 of the following: nausea; vomiting; photophobia and phonophobia. Criterion D: the participant took medication to treat the headache because he/she believed he/she was having a migraine.

    Time frame: Baseline, Weeks 1 - 12

Secondary outcomes

  1. Percentage of Participants With ≥50% Reduction From Baseline in MMDs Averaged Over Weeks 1 to 12

    A migraine day was defined as any day the participant reported a headache that met criterion A, B, C, or D: Criterion A (all of the following criteria): lasted ≥4 hours, had ≥2 of the following: unilateral location; pulsating quality; moderate or severe pain intensity; aggravation by, or causing avoidance of, routine physical activity; and was accompanied by ≥1 of the following: nausea; vomiting; photophobia and phonophobia. Criterion B: lasted ≥30 minutes and the participant had an aura with the headache. Criterion C: lasted ≥30 minutes and met ≥2 of the following criteria: lasted ≥4 hours, had ≥2 of the following: unilateral location; pulsating quality; moderate or severe pain intensity; aggravation by, or causing avoidance of, routine physical activity, and was accompanied by ≥1 of the following: nausea; vomiting; photophobia and phonophobia. Criterion D: the participant took medication to treat the headache because he/she believed he/she was having a migraine.

    Time frame: Baseline to Weeks 1 - 12

  2. Change From Baseline in the Number of MMDs Averaged Over Weeks 13 to 24

    A migraine day was defined as any day the participant reported a headache that met criterion A, B, C, or D: Criterion A (all of the following criteria): lasted ≥4 hours, had ≥2 of the following: unilateral location; pulsating quality; moderate or severe pain intensity; aggravation by, or causing avoidance of, routine physical activity; and was accompanied by ≥1 of the following: nausea; vomiting; photophobia and phonophobia. Criterion B: lasted ≥30 minutes and the participant had an aura with the headache. Criterion C: lasted ≥30 minutes and met ≥2 of the following criteria: lasted ≥4 hours, had ≥2 of the following: unilateral location; pulsating quality; moderate or severe pain intensity; aggravation by, or causing avoidance of, routine physical activity, and was accompanied by ≥1 of the following: nausea; vomiting; photophobia and phonophobia. Criterion D: the participant took medication to treat the headache because he/she believed he/she was having a migraine.

    Time frame: Baseline, Weeks 13 - 24

  3. Percentage of Participants With ≥75% Reduction From Baseline in MMDs Averaged Over Weeks 1 to 12

    A migraine day was defined as any day the participant reported a headache that met criterion A, B, C, or D: Criterion A (all of the following criteria): lasted ≥4 hours, had ≥2 of the following: unilateral location; pulsating quality; moderate or severe pain intensity; aggravation by, or causing avoidance of, routine physical activity; and was accompanied by ≥1 of the following: nausea; vomiting; photophobia and phonophobia. Criterion B: lasted ≥30 minutes and the participant had an aura with the headache. Criterion C: lasted ≥30 minutes and met ≥2 of the following criteria: lasted ≥4 hours, had ≥2 of the following: unilateral location; pulsating quality; moderate or severe pain intensity; aggravation by, or causing avoidance of, routine physical activity, and was accompanied by ≥1 of the following: nausea; vomiting; photophobia and phonophobia. Criterion D: the participant took medication to treat the headache because he/she believed he/she was having a migraine.

    Time frame: Baseline to Weeks 1 - 12

  4. Change From Baseline in the Headache Impact Test (HIT-6) Score at Week 12

    The HIT-6 (version 1.0) is a Likert-type, self-reporting questionnaire designed to assess the impact of an occurring headache and its effect on the ability to function normally in daily life. The HIT-6 contains 6 questions, each item was rated from never to always with the following response scores: never = 6, rarely = 8, sometimes = 10, very often = 11, and always = 13. The total score for the HIT-6 was the sum of each response score ranging from 36 to 78. The life impact derived from the total score was described as followed: severe (≥60), substantial (56-59), some (50-55), little to none (≤49).

    Time frame: Baseline, Week 12

  5. Percentage of Participants With ≥50% Reduction From Baseline in MMDs Averaged Over Weeks 13 to 24

    A migraine day was defined as any day the participant reported a headache that met criterion A, B, C, or D: Criterion A (all of the following criteria): lasted ≥4 hours, had ≥2 of the following: unilateral location; pulsating quality; moderate or severe pain intensity; aggravation by, or causing avoidance of, routine physical activity; and was accompanied by ≥1 of the following: nausea; vomiting; photophobia and phonophobia. Criterion B: lasted ≥30 minutes and the participant had an aura with the headache. Criterion C: lasted ≥30 minutes and met ≥2 of the following criteria: lasted ≥4 hours, had ≥2 of the following: unilateral location; pulsating quality; moderate or severe pain intensity; aggravation by, or causing avoidance of, routine physical activity, and was accompanied by ≥1 of the following: nausea; vomiting; photophobia and phonophobia. Criterion D: the participant took medication to treat the headache because he/she believed he/she was having a migraine.

    Time frame: Baseline to Weeks 13 - 24

  6. Percentage of Participants With ≥75% Reduction From Baseline in MMDs Averaged Over Weeks 13 to 24

    A migraine day was defined as any day the participant reported a headache that met criterion A, B, C, or D: Criterion A (all of the following criteria): lasted ≥4 hours, had ≥2 of the following: unilateral location; pulsating quality; moderate or severe pain intensity; aggravation by, or causing avoidance of, routine physical activity; and was accompanied by ≥1 of the following: nausea; vomiting; photophobia and phonophobia. Criterion B: lasted ≥30 minutes and the participant had an aura with the headache. Criterion C: lasted ≥30 minutes and met ≥2 of the following criteria: lasted ≥4 hours, had ≥2 of the following: unilateral location; pulsating quality; moderate or severe pain intensity; aggravation by, or causing avoidance of, routine physical activity, and was accompanied by ≥1 of the following: nausea; vomiting; photophobia and phonophobia. Criterion D: the participant took medication to treat the headache because he/she believed he/she was having a migraine.

    Time frame: Baseline to Weeks 13 - 24

  7. Percentage of Participants With 100% Reduction From Baseline in MMDs Averaged Over Weeks 1 to 12

    A migraine day was defined as any day the participant reported a headache that met criterion A, B, C, or D: Criterion A (all of the following criteria): lasted ≥4 hours, had ≥2 of the following: unilateral location; pulsating quality; moderate or severe pain intensity; aggravation by, or causing avoidance of, routine physical activity; and was accompanied by ≥1 of the following: nausea; vomiting; photophobia and phonophobia. Criterion B: lasted ≥30 minutes and the participant had an aura with the headache. Criterion C: lasted ≥30 minutes and met ≥2 of the following criteria: lasted ≥4 hours, had ≥2 of the following: unilateral location; pulsating quality; moderate or severe pain intensity; aggravation by, or causing avoidance of, routine physical activity, and was accompanied by ≥1 of the following: nausea; vomiting; photophobia and phonophobia. Criterion D: the participant took medication to treat the headache because he/she believed he/she was having a migraine.

    Time frame: Baseline to Weeks 1 - 12

  8. Percentage of Participants With ≥50% Reduction From Baseline in Monthly Headache Days (MHDs) Averaged Over Weeks 1 to 12

    A headache day was defined as a day with a headache that lasted ≥30 minutes or met the definition of a migraine day (as defined in criterion A, B, C, or D above in outcome measure 1).

    Time frame: Baseline to Weeks 1 - 12

  9. Percentage of Participants With ≥75% Reduction From Baseline in Monthly Headache Days (MHDs) Averaged Over Weeks 1 to 12

    A headache day was defined as a day with a headache that lasted ≥30 minutes or met the definition of a migraine day (as defined in criterion A, B, C, or D above in outcome measure 1).

    Time frame: Baseline to Weeks 1 - 12

  10. Percentage of Participants With 100% Reduction From Baseline in Monthly Headache Days (MHDs) Averaged Over Weeks 1 to 12

    A headache day was defined as a day with a headache that lasted ≥30 minutes or met the definition of a migraine day (as defined in criterion A, B, C, or D above in outcome measure 1).

    Time frame: Baseline to Weeks 1 - 12

  11. Change From Baseline in the Number of MHDs Averaged Over Weeks 1 to 12

    A headache day was defined as a day with a headache that lasted ≥30 minutes or met the definition of a migraine day (as defined in criterion A, B, C, or D above in outcome measure 1).

    Time frame: Baseline, Weeks 1 - 12

  12. Change From Baseline in the Percentage of Migraine Attacks With Severe Pain Intensity Averaged Over Weeks 1 to 12

    A migraine attack was defined as a headache that occurred on a single day or lasted \>1 day and that met the criteria for a migraine day (as defined in criterion A, B, C, or D above in outcome measure 1).

    Time frame: Baseline, Weeks 1 - 12

  13. Change From Baseline in the Percentage of Headache Episodes With Severe Pain Intensity Averaged Over Weeks 1 to 12

    A headache episode was defined as a headache lasted ≥30 minutes or that met the criteria for a migraine (as defined in criterion A, B, C, or D above in outcome measure 1).

    Time frame: Baseline, Weeks 1 - 12

  14. Change From Baseline in the Number of Monthly Days With Use of Acute Migraine Medication Averaged Over Weeks 1 to 12

    In the evening eDiary, participants were asked each day to fill out whether they used any of the following medications during that day: Ergotamine, triptan, analgesic, opioid, or combination analgesic. A day where the participant answered that they took any of those in the evening eDiary was considered a day with use of acute migraine medication.

    Time frame: Baseline, Weeks 1 - 12

  15. Change From Baseline in the Number of Monthly Days With Use of Acute Migraine Medication Averaged Over Weeks 13 to 24

    In the evening eDiary, participants were asked each day to fill out whether they used any of the following medications during that day: Ergotamine, triptan, analgesic, opioid, or combination analgesic. A day where the participant answered that they took any of those in the evening eDiary was considered a day with use of acute migraine medication.

    Time frame: Baseline, Weeks 13- 24

  16. Change From Baseline in the Number of MMDs With Use of Acute Medication Averaged Over Weeks 1 to 12

    Number of MMDs with acute medication usage was derived using the answer to "Did you take any medications to treat this headache?" in the headache diary. The question was asked when a participant was ending a headache. Thus, a migraine day with acute medication usage was defined as a migraine day with the extra condition that this question was answered as "Yes".

    Time frame: Baseline, Weeks 1 - 12

  17. Change From Baseline in the Number of MMDs With Use of Acute Medication Averaged Over Weeks 13 to 24

    Number of MMDs with acute medication usage was derived using the answer to "Did you take any medications to treat this headache?" in the headache diary. The question was asked when a participant was ending a headache. Thus, a migraine day with acute medication usage was defined as a migraine day with the extra condition that this question was answered as "Yes".

    Time frame: Baseline, Weeks 13 - 24

  18. Patient Global Impression of Change (PGIC) Score at Week 12

    The PGIC is a single, participant-reported item reflecting the participant's impression of change in his/her disease status since the start of the study (that is, in relation to activity limitations, symptoms, emotions, and overall quality of life). Participants rated their impression of change in disease status on a 7-point scale (1 = very much improved; 2 = much improved; 3 = minimally improved; 4 = no change; 5 = minimally worse; 6 = much worse; 7 = very much worse) where a higher score indicated worsening. Score ranges from 1 (Very Much Improved) to 7 (Very Much Worse). Lower scores indicate better health status.

    Time frame: Week 12

  19. PGIC Score at Week 24

    The PGIC is a single, participant-reported item reflecting the participant's impression of change in his/her disease status since the start of the study (that is, in relation to activity limitations, symptoms, emotions, and overall quality of life). Participants rated their impression of change in disease status on a 7-point scale (1 = very much improved; 2 = much improved; 3 = minimally improved; 4 = no change; 5 = minimally worse; 6 = much worse; 7 = very much worse) where a higher score indicated worsening. Score ranges from 1 (Very Much Improved) to 7 (Very Much Worse). Lower scores indicate better health status.

    Time frame: Week 24

  20. Change From Baseline in the Number of MMDs in Participants With Medication Overuse Headache (MOH) Averaged Over Weeks 1 to 12

    Time frame: Baseline, Weeks 1 - 12

  21. Percentage of Participants With Migraine on the Day After First Dosing

    Time frame: Day 1

  22. Most Bothersome Symptom (MBS) Score at Week 12

    Participants were asked about their most bothersome symptom associated with their migraines during the Baseline Visit. Participants were asked to rate the improvement in this symptom from baseline on a 7-point scale (1 = very much improved; 2 = much improved; 3 = minimally improved; 4 = no change; 5 = minimally worse; 6 = much worse; 7 = very much worse) where a high score indicated worsening. Score ranges from 1 (Very Much Improved) to 7 (Very Much Worse). Lower scores indicate better health status. The MBS areas included: nausea, vomiting, sensitivity to light, sensitivity to sound, mental cloudiness, fatigue, pain with activity, mood changes, and other symptoms.

    Time frame: Week 12

  23. Change From Baseline in the HIT-6 Score at Week 24

    The HIT-6 (version 1.0) is a Likert-type, self-reporting questionnaire designed to assess the impact of an occurring headache and its effect on the ability to function normally in daily life. The HIT-6 contains 6 questions, each item was rated from never to always with the following response scores: never = 6, rarely = 8, sometimes = 10, very often = 11, and always = 13. The total score for the HIT-6 was the sum of each response score ranging from 36 to 78. The life impact derived from the total score was described as followed: severe (≥60), substantial (56-59), some (50-55), little to none (≤49).

    Time frame: Baseline, Week 24

  24. Change From Baseline in the Migraine-Specific Quality of Life (MSQ) Subscores (Role Function-Restrictive, Role Function-Preventive, Emotional Function) at Week 12

    The MSQ is a participant-reported outcome designed to assess the quality of life in participants with migraine. It consists of 14 items covering 3 domains: role function restrictive (7 items); role function preventive (4 items); and emotional function (3 items). Each item was scored on a 6-point scale ranging from 1 (none of the time) to 6 (all of the time). Raw domain scores were summed and transformed to a 0- to 100-point scale. Higher scores indicated better quality of life.

    Time frame: Baseline, Week 12

  25. Change From Baseline in the Health-Related Quality of Life (EQ-5D-5L) Visual Analog Scale (VAS) Score at Week 12

    The EQ-5D-5L is a participant-reported assessment designed to measure the participant's well-being. It consists of 5 descriptive items (mobility, self-care, usual activities, pain/discomfort, and depression/anxiety) and a VAS of the overall health state. Each descriptive item was rated on a 5-point index ranging from 1 (no problems) to 5 (extreme problems). The VAS ranged from 0 (worst imaginable health state) to 100 (best imaginable health state).

    Time frame: Baseline, Week 12

  26. Change From Baseline in the MSQ Subscores (Role Function-Restrictive, Role Function-Preventive, Emotional Function) at Week 24

    The MSQ is a participant-reported outcome designed to assess the quality of life in participants with migraine. It consists of 14 items covering 3 domains: role function restrictive (7 items); role function preventive (4 items); and emotional function (3 items). Each item was scored on a 6-point scale ranging from 1 (none of the time) to 6 (all of the time). Raw domain scores were summed and transformed to a 0- to 100-point scale. Higher scores indicated better quality of life.

    Time frame: Baseline, Week 24

  27. Change From Baseline in the Health-Related Quality of Life (EQ-5D-5L) VAS Score at Week 24

    The EQ-5D-5L is a participant-reported assessment designed to measure the participant's well-being. It consists of 5 descriptive items (mobility, self-care, usual activities, pain/discomfort, and depression/anxiety) and a VAS of the overall health state. Each descriptive item was rated on a 5-point index ranging from 1 (no problems) to 5 (extreme problems). The VAS ranged from 0 (worst imaginable health state) to 100 (best imaginable health state).

    Time frame: Baseline, Week 24

  28. Change From Baseline in the Work Productivity and Activity Impairment (WPAI) Questionnaire Subscores (Absenteeism, Presenteeism, Work Productivity Loss, Activity Impairment) at Week 12

    The WPAI Questionnaire is a participant-reported instrument developed to measure the impact on work productivity and regular activities attributable to a specific health problem (migraine). Recall period is the past 7 days. It contains 6 items that measure: 1) employment status, 2) hours missed from work due to the specific health problem, 3) hours missed from work for other reasons, 4) hours actually worked, 5) degree health affected productivity while working, and 6) degree health affected productivity in regular unpaid activities. Four scores were calculated from the responses to these 6 items: absenteeism, presenteeism, work productivity loss, and activity impairment. Scores were calculated as impairment percentages (0-100%), with higher numbers indicating greater impairment and less productivity, i.e, worse outcomes.

    Time frame: Baseline, Week 12

  29. Change From Baseline in the WPAI Questionnaire Subscores (Absenteeism, Presenteeism, Work Productivity Loss, Activity Impairment) at Week 24

    The WPAI Questionnaire is a participant-reported instrument developed to measure the impact on work productivity and regular activities attributable to a specific health problem (migraine). Recall period is the past 7 days. It contains 6 items that measure: 1) employment status, 2) hours missed from work due to the specific health problem, 3) hours missed from work for other reasons, 4) hours actually worked, 5) degree health affected productivity while working, and 6) degree health affected productivity in regular unpaid activities. Four scores were calculated from the responses to these 6 items: absenteeism, presenteeism, work productivity loss, and activity impairment. Scores were calculated as impairment percentages (0-100%), with higher numbers indicating greater impairment and less productivity, i.e, worse outcomes.

    Time frame: Baseline, Week 24

  30. Percentage of Participants With ≥5-Point Reduction From Baseline to Week 12 in HIT-6 Score

    The HIT-6 (version 1.0) is a Likert-type, self-reporting questionnaire designed to assess the impact of an occurring headache and its effect on the ability to function normally in daily life. The HIT-6 contains 6 questions, each item was rated from never to always with the following response scores: never = 6, rarely = 8, sometimes = 10, very often = 11, and always = 13. The total score for the HIT-6 was the sum of each response score ranging from 36 to 78. The life impact derived from the total score was described as followed: severe (≥60), substantial (56-59), some (50-55), little to none (≤49).

    Time frame: Baseline to Week 12

  31. Percentage of Participants With ≥5-Point Reduction From Baseline to Week 24 in HIT-6 Score

    The HIT-6 (version 1.0) is a Likert-type, self-reporting questionnaire designed to assess the impact of an occurring headache and its effect on the ability to function normally in daily life. The HIT-6 contains 6 questions, each item was rated from never to always with the following response scores: never = 6, rarely = 8, sometimes = 10, very often = 11, and always = 13. The total score for the HIT-6 was the sum of each response score ranging from 36 to 78. The life impact derived from the total score was described as followed: severe (≥60), substantial (56-59), some (50-55), little to none (≤49).

    Time frame: Baseline to Week 24

  32. Health Care Resource Utilization (HCRU): Visits to a Family Doctor/General Practitioner

    Number of participants who visited to a family doctor/general practitioner has been reported.

    Time frame: Week 12

  33. HCRU: Visits to a Specialist

    Number of participants who visited to a specialist has been reported.

    Time frame: Week 12

  34. HCRU: Number of Emergency Department Visits Due to Your Migraine

    Number of participants who visited to emergency department due to your migraine has been reported.

    Time frame: Week 12

  35. HCRU: Number of Hospital Admissions Due to Migraine

    Number of participants who admitted in the hospital due to migraine has been reported.

    Time frame: Week 12

  36. HCRU: Total Number of Overnight Hospital Stays Due to Migraine

    Number of participants who had total number of overnight hospital stays due to migraine has been reported.

    Time frame: Week 12

  37. Change From Baseline in the Number of MMDs Averaged Over Weeks 25 to 36, 37 to 48, 49 to 60, and 61 to 72

    A migraine day was defined as any day the participant reported a headache that met criterion A, B, C, or D: Criterion A (all of the following criteria): lasted ≥4 hours, had ≥2 of the following: unilateral location; pulsating quality; moderate or severe pain intensity; aggravation by, or causing avoidance of, routine physical activity; and was accompanied by ≥1 of the following: nausea; vomiting; photophobia and phonophobia. Criterion B: lasted ≥30 minutes and the participant had an aura with the headache. Criterion C: lasted ≥30 minutes and met ≥2 of the following criteria: lasted ≥4 hours, had ≥2 of the following: unilateral location; pulsating quality; moderate or severe pain intensity; aggravation by, or causing avoidance of, routine physical activity, and was accompanied by ≥1 of the following: nausea; vomiting; photophobia and phonophobia. Criterion D: the participant took medication to treat the headache because he/she believed he/she was having a migraine.

    Time frame: Baseline, Weeks 25 - 36, 37 - 48, 49 - 60, and 61 - 72

  38. Percentage of Participants With ≥50% Reduction From Baseline in MMDs Averaged Over Weeks 25 to 36, 37 to 48, 49 to 60, and 61 to 72

    A migraine day was defined as any day the participant reported a headache that met criterion A, B, C, or D: Criterion A (all of the following criteria): lasted ≥4 hours, had ≥2 of the following: unilateral location; pulsating quality; moderate or severe pain intensity; aggravation by, or causing avoidance of, routine physical activity; and was accompanied by ≥1 of the following: nausea; vomiting; photophobia and phonophobia. Criterion B: lasted ≥30 minutes and the participant had an aura with the headache. Criterion C: lasted ≥30 minutes and met ≥2 of the following criteria: lasted ≥4 hours, had ≥2 of the following: unilateral location; pulsating quality; moderate or severe pain intensity; aggravation by, or causing avoidance of, routine physical activity, and was accompanied by ≥1 of the following: nausea; vomiting; photophobia and phonophobia. Criterion D: the participant took medication to treat the headache because he/she believed he/she was having a migraine.

    Time frame: Baseline to Weeks 25 - 36, 37 - 48, 49 - 60, and 61 - 72

  39. Percentage of Participants With ≥75% Reduction From Baseline in MMDs Averaged Over Weeks 25 to 36, 37 to 48, 49 to 60, and 61 to 72

    A migraine day was defined as any day the participant reported a headache that met criterion A, B, C, or D: Criterion A (all of the following criteria): lasted ≥4 hours, had ≥2 of the following: unilateral location; pulsating quality; moderate or severe pain intensity; aggravation by, or causing avoidance of, routine physical activity; and was accompanied by ≥1 of the following: nausea; vomiting; photophobia and phonophobia. Criterion B: lasted ≥30 minutes and the participant had an aura with the headache. Criterion C: lasted ≥30 minutes and met ≥2 of the following criteria: lasted ≥4 hours, had ≥2 of the following: unilateral location; pulsating quality; moderate or severe pain intensity; aggravation by, or causing avoidance of, routine physical activity, and was accompanied by ≥1 of the following: nausea; vomiting; photophobia and phonophobia. Criterion D: the participant took medication to treat the headache because he/she believed he/she was having a migraine.

    Time frame: Baseline to Weeks 25 - 36, 37 - 48, 49 - 60, and 61 - 72

  40. Change From Baseline in HIT-6 Score at Weeks 36, 48, 60, and 72

    The HIT-6 (version 1.0) is a Likert-type, self-reporting questionnaire designed to assess the impact of an occurring headache and its effect on the ability to function normally in daily life. The HIT-6 contains 6 questions, each item was rated from never to always with the following response scores: never = 6, rarely = 8, sometimes = 10, very often = 11, and always = 13. The total score for the HIT-6 was the sum of each response score ranging from 36 to 78. The life impact derived from the total score was described as followed: severe (≥60), substantial (56-59), some (50-55), little to none (≤49).

    Time frame: Baseline, Weeks 36, 48, 60, and 72

07

Results

Posted Jul 22, 2022

Participant flow

This study included 2 periods: Placebo-controlled Period - 24-week double-blind treatment period with placebo or eptinezumab and Extension Period - 48-week dose-blinded period with eptinezumab after completion of the Placebo-controlled Period.

Placebo-controlled Period (24 Weeks)
Participant flow — Placebo-controlled Period (24 Weeks)
MilestonePlaceboEptinezumab 100 mgEptinezumab 300 mg
Started299299294
Received at least 1 dose of study drug298299294
Completed293288284
Not completed61110
Withdrew: Adverse event116
Withdrew: Lack of efficacy130
Withdrew: Protocol violation011
Withdrew: Withdrawal by subject152
Withdrew: Lost to follow-up010
Withdrew: Other than specified201
Withdrew: Randomized but not treated100
Extension Period (48 Weeks)
Participant flow — Extension Period (48 Weeks)
MilestonePlaceboEptinezumab 100 mgEptinezumab 300 mg
Started0433432
Received at least 1 dose of study drug0433432
Completed0392390
Not completed04142
Withdrew: Adverse event029
Withdrew: Lack of efficacy01313
Withdrew: Withdrawal by subject02114
Withdrew: Non-compliance with study drug002
Withdrew: Protocol violation002
Withdrew: Other than specified052

Outcome measures

PrimaryChange From Baseline in the Number of Monthly Migraine Days (MMDs) Averaged Over Weeks 1 to 12

A migraine day was defined as any day the participant reported a headache that met criterion A, B, C, or D: Criterion A (all of the following criteria): lasted ≥4 hours, had ≥2 of the following: unilateral location; pulsating quality; moderate or severe pain intensity; aggravation by, or causing avoidance of, routine physical activity; and was accompanied by ≥1 of the following: nausea; vomiting; photophobia and phonophobia. Criterion B: lasted ≥30 minutes and the participant had an aura with the headache. Criterion C: lasted ≥30 minutes and met ≥2 of the following criteria: lasted ≥4 hours, had ≥2 of the following: unilateral location; pulsating quality; moderate or severe pain intensity; aggravation by, or causing avoidance of, routine physical activity, and was accompanied by ≥1 of the following: nausea; vomiting; photophobia and phonophobia. Criterion D: the participant took medication to treat the headache because he/she believed he/she was having a migraine.

Time frame:
Baseline, Weeks 1 - 12
Reported as:
Mean · days/month
Change From Baseline in the Number of Monthly Migraine Days (MMDs) Averaged Over Weeks 1 to 12
days/monthPlaceboEptinezumab 100 mgEptinezumab 300 mg
Change From Baseline in the Number of Monthly Migraine Days (MMDs) Averaged Over Weeks 1 to 12-2.1 ± 0.38-4.8 ± 0.37-5.3 ± 0.37
Statistical analysis
  • Placebo vs Eptinezumab 300 mg · Mixed Models Analysis · p = <0.0001 (Testing continued only, if the previous comparison was statistically significant. Threshold for significance: p-value \<α, where α = 0.05. Here it is test no. 1 of testing order.) · Mean difference (final values): -3.2 · 95% CI -3.9 to -2.5
  • Placebo vs Eptinezumab 100 mg · Mixed Models Analysis · p = <0.0001 (Testing continued only, if the previous comparison was statistically significant. Threshold for significance: p-value \<α, where α = 0.05. Here it is test no. 3 of testing order.) · Mean difference (final values): -2.7 · 95% CI -3.4 to -2.0
SecondaryPercentage of Participants With ≥50% Reduction From Baseline in MMDs Averaged Over Weeks 1 to 12

A migraine day was defined as any day the participant reported a headache that met criterion A, B, C, or D: Criterion A (all of the following criteria): lasted ≥4 hours, had ≥2 of the following: unilateral location; pulsating quality; moderate or severe pain intensity; aggravation by, or causing avoidance of, routine physical activity; and was accompanied by ≥1 of the following: nausea; vomiting; photophobia and phonophobia. Criterion B: lasted ≥30 minutes and the participant had an aura with the headache. Criterion C: lasted ≥30 minutes and met ≥2 of the following criteria: lasted ≥4 hours, had ≥2 of the following: unilateral location; pulsating quality; moderate or severe pain intensity; aggravation by, or causing avoidance of, routine physical activity, and was accompanied by ≥1 of the following: nausea; vomiting; photophobia and phonophobia. Criterion D: the participant took medication to treat the headache because he/she believed he/she was having a migraine.

Time frame:
Baseline to Weeks 1 - 12
Reported as:
Number · percentage of participants
Percentage of Participants With ≥50% Reduction From Baseline in MMDs Averaged Over Weeks 1 to 12
percentage of participantsPlaceboEptinezumab 100 mgEptinezumab 300 mg
Percentage of Participants With ≥50% Reduction From Baseline in MMDs Averaged Over Weeks 1 to 1213.142.149.5
Statistical analysis
  • Placebo vs Eptinezumab 300 mg · Regression, Logistic · p = <0.0001 (Testing continued only, if the previous comparison was statistically significant. Threshold for significance: p-value \<α, where α = 0.05. Here it is test no. 2 of testing order.) · Odds ratio (or): 6.58 · 95% CI 4.41 to 10.01
  • Placebo vs Eptinezumab 100 mg · Regression, Logistic · p = <0.0001 (Testing continued only, if the previous comparison was statistically significant. Threshold for significance: p-value \<α, where α = 0.05. Here it is test no. 4 of testing order.) · Odds ratio (or): 4.91 · 95% CI 3.29 to 7.47
SecondaryChange From Baseline in the Number of MMDs Averaged Over Weeks 13 to 24

A migraine day was defined as any day the participant reported a headache that met criterion A, B, C, or D: Criterion A (all of the following criteria): lasted ≥4 hours, had ≥2 of the following: unilateral location; pulsating quality; moderate or severe pain intensity; aggravation by, or causing avoidance of, routine physical activity; and was accompanied by ≥1 of the following: nausea; vomiting; photophobia and phonophobia. Criterion B: lasted ≥30 minutes and the participant had an aura with the headache. Criterion C: lasted ≥30 minutes and met ≥2 of the following criteria: lasted ≥4 hours, had ≥2 of the following: unilateral location; pulsating quality; moderate or severe pain intensity; aggravation by, or causing avoidance of, routine physical activity, and was accompanied by ≥1 of the following: nausea; vomiting; photophobia and phonophobia. Criterion D: the participant took medication to treat the headache because he/she believed he/she was having a migraine.

Time frame:
Baseline, Weeks 13 - 24
Reported as:
Mean · days/month
Change From Baseline in the Number of MMDs Averaged Over Weeks 13 to 24
days/monthPlaceboEptinezumab 100 mgEptinezumab 300 mg
Change From Baseline in the Number of MMDs Averaged Over Weeks 13 to 24-2.4 ± 0.39-5.4 ± 0.39-6.1 ± 0.39
Statistical analysis
  • Placebo vs Eptinezumab 300 mg · Mixed Models Analysis · p = <0.0001 (Threshold for significance: p-value \<α, where α = 0.05. Here it is test no. 5a of testing order.) · Mean difference (final values): -3.7 · 95% CI -4.5 to -3.0Testing continued only, if the previous comparison was statistically significant.
  • Placebo vs Eptinezumab 100 mg · Mixed Models Analysis · p = <0.0001 (Threshold for significance: The consecutive order of the smallest (p1), the second smallest (p2), and the largest p-value (p3) had to be \<α/3, \<α/2, and \<α, where α = 0.05. Here it is test no. 6a of testing order.) · Mean difference (final values): -3.0 · 95% CI -3.8 to -2.2Testing continued only, if the previous comparison was statistically significant.
SecondaryPercentage of Participants With ≥75% Reduction From Baseline in MMDs Averaged Over Weeks 1 to 12

A migraine day was defined as any day the participant reported a headache that met criterion A, B, C, or D: Criterion A (all of the following criteria): lasted ≥4 hours, had ≥2 of the following: unilateral location; pulsating quality; moderate or severe pain intensity; aggravation by, or causing avoidance of, routine physical activity; and was accompanied by ≥1 of the following: nausea; vomiting; photophobia and phonophobia. Criterion B: lasted ≥30 minutes and the participant had an aura with the headache. Criterion C: lasted ≥30 minutes and met ≥2 of the following criteria: lasted ≥4 hours, had ≥2 of the following: unilateral location; pulsating quality; moderate or severe pain intensity; aggravation by, or causing avoidance of, routine physical activity, and was accompanied by ≥1 of the following: nausea; vomiting; photophobia and phonophobia. Criterion D: the participant took medication to treat the headache because he/she believed he/she was having a migraine.

Time frame:
Baseline to Weeks 1 - 12
Reported as:
Number · percentage of participants
Percentage of Participants With ≥75% Reduction From Baseline in MMDs Averaged Over Weeks 1 to 12
percentage of participantsPlaceboEptinezumab 100 mgEptinezumab 300 mg
Percentage of Participants With ≥75% Reduction From Baseline in MMDs Averaged Over Weeks 1 to 122.015.718.8
Statistical analysis
  • Placebo vs Eptinezumab 300 mg · Regression, Logistic · p = <0.0001 (Threshold for significance: The consecutive order of the smallest (p1), the second smallest (p2), and the largest p-value (p3) had to be \<α/3, \<α/2, and \<α, where α = 0.05. Here it is test no. 5b of testing order.) · Odds ratio (or): 11.43 · 95% CI 5.22 to 30.15
  • Placebo vs Eptinezumab 100 mg · Regression, Logistic · p = <0.0001 (Threshold for significance: The consecutive order of the smallest (p1), the second smallest (p2), and the largest p-value (p3) had to be \<α/3, \<α/2, and \<α, where α = 0.05. Here it is test no. 6b of testing order.) · Odds ratio (or): 9.19 · 95% CI 4.16 to 24.35
SecondaryChange From Baseline in the Headache Impact Test (HIT-6) Score at Week 12

The HIT-6 (version 1.0) is a Likert-type, self-reporting questionnaire designed to assess the impact of an occurring headache and its effect on the ability to function normally in daily life. The HIT-6 contains 6 questions, each item was rated from never to always with the following response scores: never = 6, rarely = 8, sometimes = 10, very often = 11, and always = 13. The total score for the HIT-6 was the sum of each response score ranging from 36 to 78. The life impact derived from the total score was described as followed: severe (≥60), substantial (56-59), some (50-55), little to none (≤49).

Time frame:
Baseline, Week 12
Reported as:
Mean · units on a scale
Change From Baseline in the Headache Impact Test (HIT-6) Score at Week 12
units on a scalePlaceboEptinezumab 100 mgEptinezumab 300 mg
Change From Baseline in the Headache Impact Test (HIT-6) Score at Week 12-3.1 ± 0.61-6.9 ± 0.61-8.5 ± 0.60
Statistical analysis
  • Placebo vs Eptinezumab 300 mg · Mixed Models Analysis · p = <0.0001 (Threshold for significance: The consecutive order of the smallest (p1), the second smallest (p2), and the largest p-value (p3) had to be \<α/3, \<α/2, and \<α, where α = 0.05. Here it is test no. 5c of testing order.) · Mean difference (final values): -5.4 · 95% CI -6.7 to -4.2
  • Placebo vs Eptinezumab 100 mg · Mixed Models Analysis · p = <0.0001 (Threshold for significance: The consecutive order of the smallest (p1), the second smallest (p2), and the largest p-value (p3) had to be \<α/3, \<α/2, and \<α, where α = 0.05. Here it is test no. 6c of testing order.) · Mean difference (final values): -3.8 · 95% CI -5.0 to -2.5
SecondaryPercentage of Participants With ≥50% Reduction From Baseline in MMDs Averaged Over Weeks 13 to 24

A migraine day was defined as any day the participant reported a headache that met criterion A, B, C, or D: Criterion A (all of the following criteria): lasted ≥4 hours, had ≥2 of the following: unilateral location; pulsating quality; moderate or severe pain intensity; aggravation by, or causing avoidance of, routine physical activity; and was accompanied by ≥1 of the following: nausea; vomiting; photophobia and phonophobia. Criterion B: lasted ≥30 minutes and the participant had an aura with the headache. Criterion C: lasted ≥30 minutes and met ≥2 of the following criteria: lasted ≥4 hours, had ≥2 of the following: unilateral location; pulsating quality; moderate or severe pain intensity; aggravation by, or causing avoidance of, routine physical activity, and was accompanied by ≥1 of the following: nausea; vomiting; photophobia and phonophobia. Criterion D: the participant took medication to treat the headache because he/she believed he/she was having a migraine.

Time frame:
Baseline to Weeks 13 - 24
Reported as:
Number · percentage of participants
Percentage of Participants With ≥50% Reduction From Baseline in MMDs Averaged Over Weeks 13 to 24
percentage of participantsPlaceboEptinezumab 100 mgEptinezumab 300 mg
Percentage of Participants With ≥50% Reduction From Baseline in MMDs Averaged Over Weeks 13 to 2423.752.359.1
SecondaryPercentage of Participants With ≥75% Reduction From Baseline in MMDs Averaged Over Weeks 13 to 24

A migraine day was defined as any day the participant reported a headache that met criterion A, B, C, or D: Criterion A (all of the following criteria): lasted ≥4 hours, had ≥2 of the following: unilateral location; pulsating quality; moderate or severe pain intensity; aggravation by, or causing avoidance of, routine physical activity; and was accompanied by ≥1 of the following: nausea; vomiting; photophobia and phonophobia. Criterion B: lasted ≥30 minutes and the participant had an aura with the headache. Criterion C: lasted ≥30 minutes and met ≥2 of the following criteria: lasted ≥4 hours, had ≥2 of the following: unilateral location; pulsating quality; moderate or severe pain intensity; aggravation by, or causing avoidance of, routine physical activity, and was accompanied by ≥1 of the following: nausea; vomiting; photophobia and phonophobia. Criterion D: the participant took medication to treat the headache because he/she believed he/she was having a migraine.

Time frame:
Baseline to Weeks 13 - 24
Reported as:
Number · percentage of participants
Percentage of Participants With ≥75% Reduction From Baseline in MMDs Averaged Over Weeks 13 to 24
percentage of participantsPlaceboEptinezumab 100 mgEptinezumab 300 mg
Percentage of Participants With ≥75% Reduction From Baseline in MMDs Averaged Over Weeks 13 to 246.821.327.6
SecondaryPercentage of Participants With 100% Reduction From Baseline in MMDs Averaged Over Weeks 1 to 12

A migraine day was defined as any day the participant reported a headache that met criterion A, B, C, or D: Criterion A (all of the following criteria): lasted ≥4 hours, had ≥2 of the following: unilateral location; pulsating quality; moderate or severe pain intensity; aggravation by, or causing avoidance of, routine physical activity; and was accompanied by ≥1 of the following: nausea; vomiting; photophobia and phonophobia. Criterion B: lasted ≥30 minutes and the participant had an aura with the headache. Criterion C: lasted ≥30 minutes and met ≥2 of the following criteria: lasted ≥4 hours, had ≥2 of the following: unilateral location; pulsating quality; moderate or severe pain intensity; aggravation by, or causing avoidance of, routine physical activity, and was accompanied by ≥1 of the following: nausea; vomiting; photophobia and phonophobia. Criterion D: the participant took medication to treat the headache because he/she believed he/she was having a migraine.

Time frame:
Baseline to Weeks 1 - 12
Reported as:
Number · percentage of participants
Percentage of Participants With 100% Reduction From Baseline in MMDs Averaged Over Weeks 1 to 12
percentage of participantsPlaceboEptinezumab 100 mgEptinezumab 300 mg
Percentage of Participants With 100% Reduction From Baseline in MMDs Averaged Over Weeks 1 to 121.15.97.7
SecondaryPercentage of Participants With ≥50% Reduction From Baseline in Monthly Headache Days (MHDs) Averaged Over Weeks 1 to 12

A headache day was defined as a day with a headache that lasted ≥30 minutes or met the definition of a migraine day (as defined in criterion A, B, C, or D above in outcome measure 1).

Time frame:
Baseline to Weeks 1 - 12
Reported as:
Number · percentage of participants
Percentage of Participants With ≥50% Reduction From Baseline in Monthly Headache Days (MHDs) Averaged Over Weeks 1 to 12
percentage of participantsPlaceboEptinezumab 100 mgEptinezumab 300 mg
Percentage of Participants With ≥50% Reduction From Baseline in Monthly Headache Days (MHDs) Averaged Over Weeks 1 to 1212.839.545.7
SecondaryPercentage of Participants With ≥75% Reduction From Baseline in Monthly Headache Days (MHDs) Averaged Over Weeks 1 to 12

A headache day was defined as a day with a headache that lasted ≥30 minutes or met the definition of a migraine day (as defined in criterion A, B, C, or D above in outcome measure 1).

Time frame:
Baseline to Weeks 1 - 12
Reported as:
Number · percentage of participants
Percentage of Participants With ≥75% Reduction From Baseline in Monthly Headache Days (MHDs) Averaged Over Weeks 1 to 12
percentage of participantsPlaceboEptinezumab 100 mgEptinezumab 300 mg
Percentage of Participants With ≥75% Reduction From Baseline in Monthly Headache Days (MHDs) Averaged Over Weeks 1 to 122.315.116.4
SecondaryPercentage of Participants With 100% Reduction From Baseline in Monthly Headache Days (MHDs) Averaged Over Weeks 1 to 12

A headache day was defined as a day with a headache that lasted ≥30 minutes or met the definition of a migraine day (as defined in criterion A, B, C, or D above in outcome measure 1).

Time frame:
Baseline to Weeks 1 - 12
Reported as:
Number · percentage of participants
Percentage of Participants With 100% Reduction From Baseline in Monthly Headache Days (MHDs) Averaged Over Weeks 1 to 12
percentage of participantsPlaceboEptinezumab 100 mgEptinezumab 300 mg
Percentage of Participants With 100% Reduction From Baseline in Monthly Headache Days (MHDs) Averaged Over Weeks 1 to 121.14.15.3
SecondaryChange From Baseline in the Number of MHDs Averaged Over Weeks 1 to 12

A headache day was defined as a day with a headache that lasted ≥30 minutes or met the definition of a migraine day (as defined in criterion A, B, C, or D above in outcome measure 1).

Time frame:
Baseline, Weeks 1 - 12
Reported as:
Mean · days/month
Change From Baseline in the Number of MHDs Averaged Over Weeks 1 to 12
days/monthPlaceboEptinezumab 100 mgEptinezumab 300 mg
Change From Baseline in the Number of MHDs Averaged Over Weeks 1 to 12-2.1 ± 0.38-4.6 ± 0.37-5.1 ± 0.37
SecondaryChange From Baseline in the Percentage of Migraine Attacks With Severe Pain Intensity Averaged Over Weeks 1 to 12

A migraine attack was defined as a headache that occurred on a single day or lasted \>1 day and that met the criteria for a migraine day (as defined in criterion A, B, C, or D above in outcome measure 1).

Time frame:
Baseline, Weeks 1 - 12
Reported as:
Mean · percentage of migraine attacks
Change From Baseline in the Percentage of Migraine Attacks With Severe Pain Intensity Averaged Over Weeks 1 to 12
percentage of migraine attacksPlaceboEptinezumab 100 mgEptinezumab 300 mg
Change From Baseline in the Percentage of Migraine Attacks With Severe Pain Intensity Averaged Over Weeks 1 to 12-10.2 ± 1.91-17.9 ± 1.87-21.3 ± 1.87
SecondaryChange From Baseline in the Percentage of Headache Episodes With Severe Pain Intensity Averaged Over Weeks 1 to 12

A headache episode was defined as a headache lasted ≥30 minutes or that met the criteria for a migraine (as defined in criterion A, B, C, or D above in outcome measure 1).

Time frame:
Baseline, Weeks 1 - 12
Reported as:
Mean · percentage of headache episodes
Change From Baseline in the Percentage of Headache Episodes With Severe Pain Intensity Averaged Over Weeks 1 to 12
percentage of headache episodesPlaceboEptinezumab 100 mgEptinezumab 300 mg
Change From Baseline in the Percentage of Headache Episodes With Severe Pain Intensity Averaged Over Weeks 1 to 12-8.8 ± 1.85-16.2 ± 1.81-19.5 ± 1.81
SecondaryChange From Baseline in the Number of Monthly Days With Use of Acute Migraine Medication Averaged Over Weeks 1 to 12

In the evening eDiary, participants were asked each day to fill out whether they used any of the following medications during that day: Ergotamine, triptan, analgesic, opioid, or combination analgesic. A day where the participant answered that they took any of those in the evening eDiary was considered a day with use of acute migraine medication.

Time frame:
Baseline, Weeks 1 - 12
Reported as:
Mean · days/month
Change From Baseline in the Number of Monthly Days With Use of Acute Migraine Medication Averaged Over Weeks 1 to 12
days/monthPlaceboEptinezumab 100 mgEptinezumab 300 mg
Change From Baseline in the Number of Monthly Days With Use of Acute Migraine Medication Averaged Over Weeks 1 to 12-1.6 ± 0.34-4.1 ± 0.33-4.6 ± 0.34
SecondaryChange From Baseline in the Number of Monthly Days With Use of Acute Migraine Medication Averaged Over Weeks 13 to 24

In the evening eDiary, participants were asked each day to fill out whether they used any of the following medications during that day: Ergotamine, triptan, analgesic, opioid, or combination analgesic. A day where the participant answered that they took any of those in the evening eDiary was considered a day with use of acute migraine medication.

Time frame:
Baseline, Weeks 13- 24
Reported as:
Mean · days/month
Change From Baseline in the Number of Monthly Days With Use of Acute Migraine Medication Averaged Over Weeks 13 to 24
days/monthPlaceboEptinezumab 100 mgEptinezumab 300 mg
Change From Baseline in the Number of Monthly Days With Use of Acute Migraine Medication Averaged Over Weeks 13 to 24-1.7 ± 0.36-4.6 ± 0.36-5.2 ± 0.36
SecondaryChange From Baseline in the Number of MMDs With Use of Acute Medication Averaged Over Weeks 1 to 12

Number of MMDs with acute medication usage was derived using the answer to "Did you take any medications to treat this headache?" in the headache diary. The question was asked when a participant was ending a headache. Thus, a migraine day with acute medication usage was defined as a migraine day with the extra condition that this question was answered as "Yes".

Time frame:
Baseline, Weeks 1 - 12
Reported as:
Mean · days/month
Change From Baseline in the Number of MMDs With Use of Acute Medication Averaged Over Weeks 1 to 12
days/monthPlaceboEptinezumab 100 mgEptinezumab 300 mg
Change From Baseline in the Number of MMDs With Use of Acute Medication Averaged Over Weeks 1 to 12-2.0 ± 0.36-4.6 ± 0.36-5.2 ± 0.36
SecondaryChange From Baseline in the Number of MMDs With Use of Acute Medication Averaged Over Weeks 13 to 24

Number of MMDs with acute medication usage was derived using the answer to "Did you take any medications to treat this headache?" in the headache diary. The question was asked when a participant was ending a headache. Thus, a migraine day with acute medication usage was defined as a migraine day with the extra condition that this question was answered as "Yes".

Time frame:
Baseline, Weeks 13 - 24
Reported as:
Mean · days/month
Change From Baseline in the Number of MMDs With Use of Acute Medication Averaged Over Weeks 13 to 24
days/monthPlaceboEptinezumab 100 mgEptinezumab 300 mg
Change From Baseline in the Number of MMDs With Use of Acute Medication Averaged Over Weeks 13 to 24-2.1 ± 0.39-4.9 ± 0.39-5.8 ± 0.38
SecondaryPatient Global Impression of Change (PGIC) Score at Week 12

The PGIC is a single, participant-reported item reflecting the participant's impression of change in his/her disease status since the start of the study (that is, in relation to activity limitations, symptoms, emotions, and overall quality of life). Participants rated their impression of change in disease status on a 7-point scale (1 = very much improved; 2 = much improved; 3 = minimally improved; 4 = no change; 5 = minimally worse; 6 = much worse; 7 = very much worse) where a higher score indicated worsening. Score ranges from 1 (Very Much Improved) to 7 (Very Much Worse). Lower scores indicate better health status.

Time frame:
Week 12
Reported as:
Mean · units on a scale
Patient Global Impression of Change (PGIC) Score at Week 12
units on a scalePlaceboEptinezumab 100 mgEptinezumab 300 mg
Patient Global Impression of Change (PGIC) Score at Week 123.6 ± 0.092.6 ± 0.092.5 ± 0.09
SecondaryPGIC Score at Week 24

The PGIC is a single, participant-reported item reflecting the participant's impression of change in his/her disease status since the start of the study (that is, in relation to activity limitations, symptoms, emotions, and overall quality of life). Participants rated their impression of change in disease status on a 7-point scale (1 = very much improved; 2 = much improved; 3 = minimally improved; 4 = no change; 5 = minimally worse; 6 = much worse; 7 = very much worse) where a higher score indicated worsening. Score ranges from 1 (Very Much Improved) to 7 (Very Much Worse). Lower scores indicate better health status.

Time frame:
Week 24
Reported as:
Mean · units on a scale
PGIC Score at Week 24
units on a scalePlaceboEptinezumab 100 mgEptinezumab 300 mg
PGIC Score at Week 243.5 ± 0.092.5 ± 0.092.4 ± 0.09
SecondaryChange From Baseline in the Number of MMDs in Participants With Medication Overuse Headache (MOH) Averaged Over Weeks 1 to 12
Time frame:
Baseline, Weeks 1 - 12
Reported as:
Mean · days/month
Change From Baseline in the Number of MMDs in Participants With Medication Overuse Headache (MOH) Averaged Over Weeks 1 to 12
days/monthPlaceboEptinezumab 100 mgEptinezumab 300 mg
Change From Baseline in the Number of MMDs in Participants With Medication Overuse Headache (MOH) Averaged Over Weeks 1 to 12-2.3 ± 1.12-5.6 ± 1.07-7.3 ± 1.18
SecondaryPercentage of Participants With Migraine on the Day After First Dosing
Time frame:
Day 1
Reported as:
Number · percentage of participants
Percentage of Participants With Migraine on the Day After First Dosing
percentage of participantsPlaceboEptinezumab 100 mgEptinezumab 300 mg
Percentage of Participants With Migraine on the Day After First Dosing43.727.224.4
SecondaryMost Bothersome Symptom (MBS) Score at Week 12

Participants were asked about their most bothersome symptom associated with their migraines during the Baseline Visit. Participants were asked to rate the improvement in this symptom from baseline on a 7-point scale (1 = very much improved; 2 = much improved; 3 = minimally improved; 4 = no change; 5 = minimally worse; 6 = much worse; 7 = very much worse) where a high score indicated worsening. Score ranges from 1 (Very Much Improved) to 7 (Very Much Worse). Lower scores indicate better health status. The MBS areas included: nausea, vomiting, sensitivity to light, sensitivity to sound, mental cloudiness, fatigue, pain with activity, mood changes, and other symptoms.

Time frame:
Week 12
Reported as:
Mean · units on a scale
Most Bothersome Symptom (MBS) Score at Week 12
units on a scalePlaceboEptinezumab 100 mgEptinezumab 300 mg
Most Bothersome Symptom (MBS) Score at Week 123.7 ± 0.092.8 ± 0.092.7 ± 0.09
SecondaryChange From Baseline in the HIT-6 Score at Week 24

The HIT-6 (version 1.0) is a Likert-type, self-reporting questionnaire designed to assess the impact of an occurring headache and its effect on the ability to function normally in daily life. The HIT-6 contains 6 questions, each item was rated from never to always with the following response scores: never = 6, rarely = 8, sometimes = 10, very often = 11, and always = 13. The total score for the HIT-6 was the sum of each response score ranging from 36 to 78. The life impact derived from the total score was described as followed: severe (≥60), substantial (56-59), some (50-55), little to none (≤49).

Time frame:
Baseline, Week 24
Reported as:
Mean · units on a scale
Change From Baseline in the HIT-6 Score at Week 24
units on a scalePlaceboEptinezumab 100 mgEptinezumab 300 mg
Change From Baseline in the HIT-6 Score at Week 24-3.9 ± 0.63-8.9 ± 0.63-9.9 ± 0.62
SecondaryChange From Baseline in the Migraine-Specific Quality of Life (MSQ) Subscores (Role Function-Restrictive, Role Function-Preventive, Emotional Function) at Week 12

The MSQ is a participant-reported outcome designed to assess the quality of life in participants with migraine. It consists of 14 items covering 3 domains: role function restrictive (7 items); role function preventive (4 items); and emotional function (3 items). Each item was scored on a 6-point scale ranging from 1 (none of the time) to 6 (all of the time). Raw domain scores were summed and transformed to a 0- to 100-point scale. Higher scores indicated better quality of life.

Time frame:
Baseline, Week 12
Reported as:
Mean · units on a scale
Change From Baseline in the Migraine-Specific Quality of Life (MSQ) Subscores (Role Function-Restrictive, Role Function-Preventive, Emotional Function) at Week 12
units on a scalePlaceboEptinezumab 100 mgEptinezumab 300 mg
MSQ Role Function-Restrictive13.7 ± 1.7525.0 ± 1.7528.7 ± 1.72
MSQ Role Function-Preventive11.6 ± 1.6322.7 ± 1.6425.0 ± 1.61
MSQ Emotional Function9.6 ± 1.8320.6 ± 1.8423.1 ± 1.80
SecondaryChange From Baseline in the Health-Related Quality of Life (EQ-5D-5L) Visual Analog Scale (VAS) Score at Week 12

The EQ-5D-5L is a participant-reported assessment designed to measure the participant's well-being. It consists of 5 descriptive items (mobility, self-care, usual activities, pain/discomfort, and depression/anxiety) and a VAS of the overall health state. Each descriptive item was rated on a 5-point index ranging from 1 (no problems) to 5 (extreme problems). The VAS ranged from 0 (worst imaginable health state) to 100 (best imaginable health state).

Time frame:
Baseline, Week 12
Reported as:
Mean · units on a scale
Change From Baseline in the Health-Related Quality of Life (EQ-5D-5L) Visual Analog Scale (VAS) Score at Week 12
units on a scalePlaceboEptinezumab 100 mgEptinezumab 300 mg
Change From Baseline in the Health-Related Quality of Life (EQ-5D-5L) Visual Analog Scale (VAS) Score at Week 12-3.1 ± 1.392.0 ± 1.404.4 ± 1.38
SecondaryChange From Baseline in the MSQ Subscores (Role Function-Restrictive, Role Function-Preventive, Emotional Function) at Week 24

The MSQ is a participant-reported outcome designed to assess the quality of life in participants with migraine. It consists of 14 items covering 3 domains: role function restrictive (7 items); role function preventive (4 items); and emotional function (3 items). Each item was scored on a 6-point scale ranging from 1 (none of the time) to 6 (all of the time). Raw domain scores were summed and transformed to a 0- to 100-point scale. Higher scores indicated better quality of life.

Time frame:
Baseline, Week 24
Reported as:
Mean · units on a scale
Change From Baseline in the MSQ Subscores (Role Function-Restrictive, Role Function-Preventive, Emotional Function) at Week 24
units on a scalePlaceboEptinezumab 100 mgEptinezumab 300 mg
MSQ Role Function-Restrictive15.0 ± 1.7630.1 ± 1.7830.0 ± 1.73
MSQ Role Function-Preventive13.1 ± 1.6325.7 ± 1.6526.3 ± 1.61
MSQ Emotional Function9.9 ± 1.8424.1 ± 1.8624.1 ± 1.81
SecondaryChange From Baseline in the Health-Related Quality of Life (EQ-5D-5L) VAS Score at Week 24

The EQ-5D-5L is a participant-reported assessment designed to measure the participant's well-being. It consists of 5 descriptive items (mobility, self-care, usual activities, pain/discomfort, and depression/anxiety) and a VAS of the overall health state. Each descriptive item was rated on a 5-point index ranging from 1 (no problems) to 5 (extreme problems). The VAS ranged from 0 (worst imaginable health state) to 100 (best imaginable health state).

Time frame:
Baseline, Week 24
Reported as:
Mean · units on a scale
Change From Baseline in the Health-Related Quality of Life (EQ-5D-5L) VAS Score at Week 24
units on a scalePlaceboEptinezumab 100 mgEptinezumab 300 mg
Change From Baseline in the Health-Related Quality of Life (EQ-5D-5L) VAS Score at Week 24-2.8 ± 1.382.0 ± 1.405.2 ± 1.37
SecondaryChange From Baseline in the Work Productivity and Activity Impairment (WPAI) Questionnaire Subscores (Absenteeism, Presenteeism, Work Productivity Loss, Activity Impairment) at Week 12

The WPAI Questionnaire is a participant-reported instrument developed to measure the impact on work productivity and regular activities attributable to a specific health problem (migraine). Recall period is the past 7 days. It contains 6 items that measure: 1) employment status, 2) hours missed from work due to the specific health problem, 3) hours missed from work for other reasons, 4) hours actually worked, 5) degree health affected productivity while working, and 6) degree health affected productivity in regular unpaid activities. Four scores were calculated from the responses to these 6 items: absenteeism, presenteeism, work productivity loss, and activity impairment. Scores were calculated as impairment percentages (0-100%), with higher numbers indicating greater impairment and less productivity, i.e, worse outcomes.

Time frame:
Baseline, Week 12
Reported as:
Mean · units on a scale
Change From Baseline in the Work Productivity and Activity Impairment (WPAI) Questionnaire Subscores (Absenteeism, Presenteeism, Work Productivity Loss, Activity Impairment) at Week 12
units on a scalePlaceboEptinezumab 100 mgEptinezumab 300 mg
Absenteeism-0.1 ± 1.49-5.8 ± 1.53-3.8 ± 1.50
Presenteeism-9.9 ± 2.42-19.0 ± 2.46-23.3 ± 2.40
Work productivity loss-9.7 ± 2.56-19.5 ± 2.61-24.0 ± 2.54
Activity impairment-11.2 ± 2.07-21.3 ± 2.07-23.8 ± 2.05
SecondaryChange From Baseline in the WPAI Questionnaire Subscores (Absenteeism, Presenteeism, Work Productivity Loss, Activity Impairment) at Week 24

The WPAI Questionnaire is a participant-reported instrument developed to measure the impact on work productivity and regular activities attributable to a specific health problem (migraine). Recall period is the past 7 days. It contains 6 items that measure: 1) employment status, 2) hours missed from work due to the specific health problem, 3) hours missed from work for other reasons, 4) hours actually worked, 5) degree health affected productivity while working, and 6) degree health affected productivity in regular unpaid activities. Four scores were calculated from the responses to these 6 items: absenteeism, presenteeism, work productivity loss, and activity impairment. Scores were calculated as impairment percentages (0-100%), with higher numbers indicating greater impairment and less productivity, i.e, worse outcomes.

Time frame:
Baseline, Week 24
Reported as:
Mean · units on a scale
Change From Baseline in the WPAI Questionnaire Subscores (Absenteeism, Presenteeism, Work Productivity Loss, Activity Impairment) at Week 24
units on a scalePlaceboEptinezumab 100 mgEptinezumab 300 mg
Absenteeism-0.7 ± 1.46-5.2 ± 1.53-5.4 ± 1.47
Presenteeism-7.5 ± 2.49-22.2 ± 2.59-19.3 ± 2.46
Work productivity loss-7.2 ± 2.62-22.6 ± 2.73-20.2 ± 2.60
Activity impairment-10.1 ± 2.07-24.7 ± 2.09-22.6 ± 2.04
SecondaryPercentage of Participants With ≥5-Point Reduction From Baseline to Week 12 in HIT-6 Score

The HIT-6 (version 1.0) is a Likert-type, self-reporting questionnaire designed to assess the impact of an occurring headache and its effect on the ability to function normally in daily life. The HIT-6 contains 6 questions, each item was rated from never to always with the following response scores: never = 6, rarely = 8, sometimes = 10, very often = 11, and always = 13. The total score for the HIT-6 was the sum of each response score ranging from 36 to 78. The life impact derived from the total score was described as followed: severe (≥60), substantial (56-59), some (50-55), little to none (≤49).

Time frame:
Baseline to Week 12
Reported as:
Number · percentage of participants
Percentage of Participants With ≥5-Point Reduction From Baseline to Week 12 in HIT-6 Score
percentage of participantsPlaceboEptinezumab 100 mgEptinezumab 300 mg
Percentage of Participants With ≥5-Point Reduction From Baseline to Week 12 in HIT-6 Score39.962.162.0
SecondaryPercentage of Participants With ≥5-Point Reduction From Baseline to Week 24 in HIT-6 Score

The HIT-6 (version 1.0) is a Likert-type, self-reporting questionnaire designed to assess the impact of an occurring headache and its effect on the ability to function normally in daily life. The HIT-6 contains 6 questions, each item was rated from never to always with the following response scores: never = 6, rarely = 8, sometimes = 10, very often = 11, and always = 13. The total score for the HIT-6 was the sum of each response score ranging from 36 to 78. The life impact derived from the total score was described as followed: severe (≥60), substantial (56-59), some (50-55), little to none (≤49).

Time frame:
Baseline to Week 24
Reported as:
Number · percentage of participants
Percentage of Participants With ≥5-Point Reduction From Baseline to Week 24 in HIT-6 Score
percentage of participantsPlaceboEptinezumab 100 mgEptinezumab 300 mg
Percentage of Participants With ≥5-Point Reduction From Baseline to Week 24 in HIT-6 Score46.272.171.6
SecondaryHealth Care Resource Utilization (HCRU): Visits to a Family Doctor/General Practitioner

Number of participants who visited to a family doctor/general practitioner has been reported.

Time frame:
Week 12
Reported as:
Count of participants · Participants
Health Care Resource Utilization (HCRU): Visits to a Family Doctor/General Practitioner
ParticipantsPlaceboEptinezumab 100 mgEptinezumab 300 mg
0 Visit244259256
1 Visit352222
2 Visits656
3 Visits723
4 Visits111
5 Visits121
6 Visits200
8 Visits100
SecondaryHCRU: Visits to a Specialist

Number of participants who visited to a specialist has been reported.

Time frame:
Week 12
Reported as:
Count of participants · Participants
HCRU: Visits to a Specialist
ParticipantsPlaceboEptinezumab 100 mgEptinezumab 300 mg
0 Visit249256257
1 Visit333124
2 Visits224
3 Visits724
5 Visits100
6 Visits400
8 Visits100
SecondaryHCRU: Number of Emergency Department Visits Due to Your Migraine

Number of participants who visited to emergency department due to your migraine has been reported.

Time frame:
Week 12
Reported as:
Count of participants · Participants
HCRU: Number of Emergency Department Visits Due to Your Migraine
ParticipantsPlaceboEptinezumab 100 mgEptinezumab 300 mg
0 Visit289289285
1 Visit613
2 Visits011
3 Visits100
8 Visits100
SecondaryHCRU: Number of Hospital Admissions Due to Migraine

Number of participants who admitted in the hospital due to migraine has been reported.

Time frame:
Week 12
Reported as:
Count of participants · Participants
HCRU: Number of Hospital Admissions Due to Migraine
ParticipantsPlaceboEptinezumab 100 mgEptinezumab 300 mg
0 Visit295289287
1 Visit112
2 Visits010
4 Visits100
SecondaryHCRU: Total Number of Overnight Hospital Stays Due to Migraine

Number of participants who had total number of overnight hospital stays due to migraine has been reported.

Time frame:
Week 12
Reported as:
Count of participants · Participants
HCRU: Total Number of Overnight Hospital Stays Due to Migraine
ParticipantsPlaceboEptinezumab 100 mgEptinezumab 300 mg
0 Visit295290289
1 Visit100
3 Visits110
SecondaryChange From Baseline in the Number of MMDs Averaged Over Weeks 25 to 36, 37 to 48, 49 to 60, and 61 to 72

A migraine day was defined as any day the participant reported a headache that met criterion A, B, C, or D: Criterion A (all of the following criteria): lasted ≥4 hours, had ≥2 of the following: unilateral location; pulsating quality; moderate or severe pain intensity; aggravation by, or causing avoidance of, routine physical activity; and was accompanied by ≥1 of the following: nausea; vomiting; photophobia and phonophobia. Criterion B: lasted ≥30 minutes and the participant had an aura with the headache. Criterion C: lasted ≥30 minutes and met ≥2 of the following criteria: lasted ≥4 hours, had ≥2 of the following: unilateral location; pulsating quality; moderate or severe pain intensity; aggravation by, or causing avoidance of, routine physical activity, and was accompanied by ≥1 of the following: nausea; vomiting; photophobia and phonophobia. Criterion D: the participant took medication to treat the headache because he/she believed he/she was having a migraine.

Time frame:
Baseline, Weeks 25 - 36, 37 - 48, 49 - 60, and 61 - 72
Reported as:
Mean · days/month
Change From Baseline in the Number of MMDs Averaged Over Weeks 25 to 36, 37 to 48, 49 to 60, and 61 to 72
days/monthPlacebo to Eptinezumab 100 mgPlacebo to Eptinezumab 300 mgEptinezumab 100 mg to Eptinezumab 100 mgEptinezumab 300 mg to Eptinezumab 300 mg
Change at Weeks 25-36-4.7 ± 0.49-6.1 ± 0.49-5.8 ± 0.39-5.9 ± 0.39
Change at Weeks 37-48-5.0 ± 0.50-6.0 ± 0.50-5.8 ± 0.40-6.0 ± 0.40
Change at Weeks 49-60-5.6 ± 0.51-6.6 ± 0.51-5.8 ± 0.41-6.0 ± 0.41
Change at Weeks 61-72-5.9 ± 0.51-6.8 ± 0.51-6.6 ± 0.41-6.5 ± 0.41
SecondaryPercentage of Participants With ≥50% Reduction From Baseline in MMDs Averaged Over Weeks 25 to 36, 37 to 48, 49 to 60, and 61 to 72

A migraine day was defined as any day the participant reported a headache that met criterion A, B, C, or D: Criterion A (all of the following criteria): lasted ≥4 hours, had ≥2 of the following: unilateral location; pulsating quality; moderate or severe pain intensity; aggravation by, or causing avoidance of, routine physical activity; and was accompanied by ≥1 of the following: nausea; vomiting; photophobia and phonophobia. Criterion B: lasted ≥30 minutes and the participant had an aura with the headache. Criterion C: lasted ≥30 minutes and met ≥2 of the following criteria: lasted ≥4 hours, had ≥2 of the following: unilateral location; pulsating quality; moderate or severe pain intensity; aggravation by, or causing avoidance of, routine physical activity, and was accompanied by ≥1 of the following: nausea; vomiting; photophobia and phonophobia. Criterion D: the participant took medication to treat the headache because he/she believed he/she was having a migraine.

Time frame:
Baseline to Weeks 25 - 36, 37 - 48, 49 - 60, and 61 - 72
Reported as:
Number · percentage of participants
Percentage of Participants With ≥50% Reduction From Baseline in MMDs Averaged Over Weeks 25 to 36, 37 to 48, 49 to 60, and 61 to 72
percentage of participantsPlacebo to Eptinezumab 100 mgPlacebo to Eptinezumab 300 mgEptinezumab 100 mg to Eptinezumab 100 mgEptinezumab 300 mg to Eptinezumab 300 mg
Weeks 25-3648.663.059.661.0
Weeks 37-4849.360.360.661.9
Weeks 49-6059.768.662.662.3
Weeks 61-7263.569.968.365.9
SecondaryPercentage of Participants With ≥75% Reduction From Baseline in MMDs Averaged Over Weeks 25 to 36, 37 to 48, 49 to 60, and 61 to 72

A migraine day was defined as any day the participant reported a headache that met criterion A, B, C, or D: Criterion A (all of the following criteria): lasted ≥4 hours, had ≥2 of the following: unilateral location; pulsating quality; moderate or severe pain intensity; aggravation by, or causing avoidance of, routine physical activity; and was accompanied by ≥1 of the following: nausea; vomiting; photophobia and phonophobia. Criterion B: lasted ≥30 minutes and the participant had an aura with the headache. Criterion C: lasted ≥30 minutes and met ≥2 of the following criteria: lasted ≥4 hours, had ≥2 of the following: unilateral location; pulsating quality; moderate or severe pain intensity; aggravation by, or causing avoidance of, routine physical activity, and was accompanied by ≥1 of the following: nausea; vomiting; photophobia and phonophobia. Criterion D: the participant took medication to treat the headache because he/she believed he/she was having a migraine.

Time frame:
Baseline to Weeks 25 - 36, 37 - 48, 49 - 60, and 61 - 72
Reported as:
Number · percentage of participants
Percentage of Participants With ≥75% Reduction From Baseline in MMDs Averaged Over Weeks 25 to 36, 37 to 48, 49 to 60, and 61 to 72
percentage of participantsPlacebo to Eptinezumab 100 mgPlacebo to Eptinezumab 300 mgEptinezumab 100 mg to Eptinezumab 100 mgEptinezumab 300 mg to Eptinezumab 300 mg
Weeks 25-3619.428.125.931.2
Weeks 37-4827.930.831.632.6
Weeks 49-6032.133.629.338.9
Weeks 61-7236.539.037.744.7
SecondaryChange From Baseline in HIT-6 Score at Weeks 36, 48, 60, and 72

The HIT-6 (version 1.0) is a Likert-type, self-reporting questionnaire designed to assess the impact of an occurring headache and its effect on the ability to function normally in daily life. The HIT-6 contains 6 questions, each item was rated from never to always with the following response scores: never = 6, rarely = 8, sometimes = 10, very often = 11, and always = 13. The total score for the HIT-6 was the sum of each response score ranging from 36 to 78. The life impact derived from the total score was described as followed: severe (≥60), substantial (56-59), some (50-55), little to none (≤49).

Time frame:
Baseline, Weeks 36, 48, 60, and 72
Reported as:
Mean · units on a scale
Change From Baseline in HIT-6 Score at Weeks 36, 48, 60, and 72
units on a scalePlacebo to Eptinezumab 100 mgPlacebo to Eptinezumab 300 mgEptinezumab 100 mg to Eptinezumab 100 mgEptinezumab 300 mg to Eptinezumab 300 mg
Change at Week 36-10.01 ± 0.69-12.15 ± 0.73-10.99 ± 0.57-12.0 ± 0.56
Change at Week 48-10.71 ± 0.77-12.71 ± 0.75-12.55 ± 0.59-12.68 ± 0.60
Change at Week 60-12.54 ± 0.80-13.21 ± 0.71-12.57 ± 0.56-13.15 ± 0.59
Change at Week 72-12.68 ± 0.87-15.02 ± 0.78-13.28 ± 0.63-14.13 ± 0.63

Adverse events

Collected over Baseline up to Week 72. Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo-controlled Period: Placebo0/298 (0%)3/298 (1%)85/298 (28.5%)
Placebo-controlled Period: Eptinezumab 100 mg0/299 (0%)6/299 (2%)95/299 (31.8%)
Placebo-controlled Period: Eptinezumab 300 mg0/294 (0%)7/294 (2.4%)90/294 (30.6%)
Extension Period: Placebo to Eptinezumab 100 mg0/145 (0%)2/145 (1.4%)57/145 (39.3%)
Extension Period: Placebo to Eptinezumab 300 mg0/148 (0%)7/148 (4.7%)62/148 (41.9%)
Extension Period: Eptinezumab 100 mg to Eptinezumab 100 mg0/288 (0%)9/288 (3.1%)133/288 (46.2%)
Extension Period: Eptinezumab 300 mg to Eptinezumab 300 mg0/284 (0%)9/284 (3.2%)118/284 (41.5%)
Most frequent serious events
Showing 10 of 43
Most frequent serious events
EventPlacebo-controlled Period: PlaceboPlacebo-controlled Period: Eptinezumab 100 mgPlacebo-controlled Period: Eptinezumab 300 mgExtension Period: Placebo to Eptinezumab 100 mgExtension Period: Placebo to Eptinezumab 300 mgExtension Period: Eptinezumab 100 mg to Eptinezumab 100 mgExtension Period: Eptinezumab 300 mg to Eptinezumab 300 mg
Inguinal herniaGastrointestinal disorders0/2980/2990/2941/1450/1480/2881/284
Colorectal adenocarcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/2980/2990/2941/1450/1480/2880/284
Anaphylactic reactionImmune system disorders0/2980/2992/2940/1450/1480/2881/284
COVID-19Infections and infestations0/2981/2992/2940/1450/1480/2880/284
CholelithiasisHepatobiliary disorders0/2981/2990/2940/1451/1480/2880/284
Intervertebral disc protrusionMusculoskeletal and connective tissue disorders0/2980/2991/2940/1451/1480/2880/284
PeriarthritisMusculoskeletal and connective tissue disorders0/2980/2990/2940/1451/1480/2880/284
Breast cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/2980/2991/2940/1451/1480/2880/284
Eye painEye disorders0/2980/2990/2940/1451/1480/2880/284
Chronic sinusitisInfections and infestations0/2980/2990/2940/1451/1480/2880/284
Most frequent other events
Showing 10 of 64
Most frequent other events
EventPlacebo-controlled Period: PlaceboPlacebo-controlled Period: Eptinezumab 100 mgPlacebo-controlled Period: Eptinezumab 300 mgExtension Period: Placebo to Eptinezumab 100 mgExtension Period: Placebo to Eptinezumab 300 mgExtension Period: Eptinezumab 100 mg to Eptinezumab 100 mgExtension Period: Eptinezumab 300 mg to Eptinezumab 300 mg
COVID-19Infections and infestations16/29819/29915/29425/14531/14863/28863/284
NasopharyngitisInfections and infestations3/2985/2999/2947/14513/14819/28827/284
Upper respiratory tract infectionInfections and infestations1/2984/2992/2944/1456/14813/2888/284
NauseaGastrointestinal disorders4/2984/2995/2941/1455/1482/2883/284
CystitisInfections and infestations1/2980/2992/2940/1455/1481/2883/284
Back painMusculoskeletal and connective tissue disorders4/2986/2993/2941/1452/1488/2882/284
Urinary tract infectionInfections and infestations5/2981/2995/2943/1454/1483/2884/284
MigraineNervous system disorders3/2981/2993/2940/1451/1487/2882/284
ArthralgiaMusculoskeletal and connective tissue disorders0/2986/2994/2941/1452/1486/2886/284
PruritusSkin and subcutaneous tissue disorders0/2982/2992/2941/1450/1482/2886/284

Baseline characteristics

Full analysis set (FAS) included all randomized participants who had a valid baseline assessment and at least 1 valid post-baseline 4-week assessment of monthly migraine days (MMDs) in Weeks 1 to 12.

Age, Continuous
Age, Continuous(years)PlaceboEptinezumab 100 mgEptinezumab 300 mgTotal
Mean43.8 ± 10.8344.6 ± 10.7643.1 ± 10.243.8 ± 10.61
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboEptinezumab 100 mgEptinezumab 300 mgTotal
Female263277260800
Male35223390
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PlaceboEptinezumab 100 mgEptinezumab 300 mgTotal
Race — White285288281854
Race — Other2002
Race — Unknown11111234
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PlaceboEptinezumab 100 mgEptinezumab 300 mgTotal
Ethnicity — Hispanic or Latino0011
Ethnicity — Not Hispanic or Latino2125
Ethnicity — Not collected296298290884
Monthly Migraine Days (MMDs)
Monthly Migraine Days (MMDs)(days/month)PlaceboEptinezumab 100 mgEptinezumab 300 mgTotal
Mean13.9 ± 5.7213.8 ± 5.5813.7 ± 5.4413.8 ± 5.57
Monthly Headache Days (MHDs)
Monthly Headache Days (MHDs)(days/month)PlaceboEptinezumab 100 mgEptinezumab 300 mgTotal
Mean14.5 ± 5.7914.5 ± 5.6314.4 ± 5.4514.5 ± 5.62
Headache Impact Test (HIT-6) Score
Headache Impact Test (HIT-6) Score(units on a scale)PlaceboEptinezumab 100 mgEptinezumab 300 mgTotal
Mean66.2 ± 4.3866.6 ± 4.766.5 ± 4.4166.4 ± 4.5
Percentage of Migraine Attacks With Severe Pain Intensity
Percentage of Migraine Attacks With Severe Pain Intensity(percentage of migraine attacks)PlaceboEptinezumab 100 mgEptinezumab 300 mgTotal
Mean40.4 ± 29.7447.1 ± 29.8243.9 ± 28.443.8 ± 29.43

6 further baseline measures are reported on the registry.

08

Study locations

138 sites
  • Diablo Clinical Research
    Walnut Creek, California 94598, United States
  • Sarkis Clinical Trials - Gainesville
    Gainesville, Florida 32607, United States
  • Accel Research Sites - Maitland
    Maitland, Florida 32751, United States
  • Michigan Headache and Neurological Institute
    Ann Arbor, Michigan 48104-5131, United States
  • Clinical Research Institute Inc. - Minneapolis
    Minneapolis, Minnesota 55402, United States
  • Albuqerque Clinical Trials
    Albuquerque, New Mexico 87102, United States
  • Dent Neurologic Institute - Amherst
    Amherst, New York 14226, United States
  • Integrative Clinical Trials
    Brooklyn, New York 11229, United States
  • CTI Clinical Research Center
    Cincinnati, Ohio 45212, United States
  • Hometown Urgent Care & Occupational Health/Hometown Research - Huber Heights
    Dayton, Ohio 45424, United States
  • Lynn Health Science Institute - Oklahoma City
    Oklahoma City, Oklahoma 73112, United States
  • Clinical Neuroscience Solutions - Memphis
    Memphis, Tennessee 38119, United States
  • Northwest Clinical Research Center (NWCRC)
    Bellevue, Washington 98007, United States
  • Northwest Neurological
    Spokane, Washington 99202, United States
  • Universitair Ziekenhuis Brussel
    Brussels, Bruxelles-Capitale 1090, Belgium
  • Jessa Ziekenhuis - Campus Virga Jesse
    Hasselt, Limburg 3500, Belgium
  • Universitair Ziekenhuis Gent
    Gent, Oost-Vlaanderen 9000, Belgium
  • Algemeen Ziekenhuis Sint-Jan Brugge-Oostende - Campus Sint-Jan
    Brugge, West-Vlaanderen 8000, Belgium
  • Multiprofile Hospital for Active Treatment in Neurology and Psychiatry Sveti Naum
    Sofia, Sofia City 1113, Bulgaria
  • First Multiprofile Hospital for Active Treatment - Sofia
    Sofia, Sofia City 1142, Bulgaria
  • Multiprofile Hospital for Active Treatment Heart and Brain EAD
    Pleven, 5804, Bulgaria
  • Medical Center - Teodora EOOD
    Ruse, 7012, Bulgaria
  • Acibadem City Clinic Tokuda Hospital
    Sofia, 1407, Bulgaria
  • Medical Center Medica Plus
    Veliko Tarnovo, 5006, Bulgaria
  • MUDr. Helena Hojdíkova s.r.o. Neurologicka Ambulance
    Hradec Kralove, Hradec Kralové 500 03, Czechia
  • Vestra Clinics
    Rychnov nad Kneznou, Hradec Kralové 516 01, Czechia
  • CCR Brno
    Brno, Jihormoravsky Kraj 602 00, Czechia
  • Fakultni nemocnice Ostrava
    Ostrava-Poruba-Poruba, Moravian-Silesian 708 52, Czechia
  • Fakultní Thomayerova nemocnice
    Praha 4, Prague 140 59, Czechia
  • Neurologicka Ambulance - Forbeli
    Praha 6, Prague 160 00, Czechia
  • Neuropsychiatrie S.R.O.
    Praha 6, Prague 160 00, Czechia
  • Institut Neuropsychiatrické Péce
    Praha 8, Prague 186 00, Czechia
  • CCR Prague
    Praha 3, Praha 130 00, Czechia
  • CCR Ostrava
    Ostrava, Severomoravsky Kraj 702 00, Czechia
  • Fakultní Nemocnice u sv. Anny v Brne
    Brno, South Moravian 656 91, Czechia
  • Nemocnice Jihlava
    Jihlava, 586 01, Czechia
  • Neurosanatio s.r.o
    Litomyshl, 57001, Czechia
  • Neurologie, MP-neuro s.r.o., poliklinika Modry pavilon
    Slezska Ostrava, 710 00, Czechia
  • NeuroMed Zlín s.r.o.
    Zlín, 760 01, Czechia
  • Rigshospitalet Glostrup
    Glostrup, Hovedstaden 2600, Denmark
  • Odense Universitetshospital
    Odense, Syddanmark 5000, Denmark
  • Sydvestjysk Sygehus - Esbjerg
    Esbjerg, 6700, Denmark
  • Tampereen Yliopistollinen Sairaala
    Tampere, Länsi-Suomen Lääni 33520, Finland
  • Terveystalo Ruoholahti
    Helsinki, Southern Finland 00180, Finland
  • Terveystalo Turku Pulssi
    Turku, Western Finland 20100, Finland
  • Itä-Suomen Yliopisto - Kuopion Kampus
    Kuopio, 70210, Finland
  • Terveystalo Tampere
    Tampere, 33100, Finland
  • Hôpital Cimiez
    Nice Cedex 1, Côte-d'Or 91179 - 06003, France
  • Hôpital Charles-Nicolle
    Rouen, Haute-Normandie 76000, France
  • Hôpital Roger Salengro
    Lille Cedex, Nord 59037, France
  • Centre Hosptitalier Universitaire d'Angers
    Angers, Pays De La Loire 49 933, France
  • Assistance Publique Hôpitaux de Marseille
    Marseille cedex 5, Provence Alpes Cote D'Azure 13 354, France
  • Hôpital Pierre Wertheimer
    Bron, Rhone-Alps 69500, France
  • Helsicore - Israeli-Georgian Medical Research Clinic
    T'bilisi, Tbilisi 0112, Georgia
  • LLC Todua Clinic
    T'bilisi, Tbilisi 0112, Georgia
  • Pineo Medical Ecosystem
    Tbilisi, 0114, Georgia
  • Archangel Saint Michael Multiprofile Clinical Hospital
    Tbilisi, 0159, Georgia
  • Aversi Clinic - Central Branch
    Tbilisi, 0160, Georgia
  • Mediclub Georgia Medical
    Tbilisi, 0160, Georgia
  • Jerarsi Clinic
    Tbilisi, 0167, Georgia
  • Malkhaz Katsiashvili Multiprofile Emergency Center
    Tbilisi, 0172, Georgia
  • Simon Khechinashvili University Hospital
    Tbilisi, 0179, Georgia
  • Consilium Medulla Multiprofile Clinic
    Tbilisi, 0186, Georgia
  • MVZ Dr. Roth & Kollegen GbR
    Ostfildern, Baden-Wuerttemberg 73760, Germany
  • Neuroplus
    Mannheim, Baden-Württemberg 68163, Germany
  • NeuroConcept AG
    Stuttgart, Baden-Württemberg 70182, Germany
  • Praxis Dr. Steinwachs
    Nürnberg, Bayern 90402, Germany
  • CTC North
    Hamburg, Hamburg (Hansestadt) 20251, Germany
  • Migräne- und Kopfschmerzklinik Königstein
    Königstein Im Taunus, Hessen 61462, Germany
  • Synexus - Prüfzentrum Frankfurt/Main
    Frankfurt am Main, Hesse 60313, Germany
  • Studienzentrum Nord West
    Westerstede, Niedersachsen 26655, Germany
  • Neurozentrum Bielefeld
    Bielefeld, Nordrhein-Westfalen 33647, Germany
  • Neurologische Praxis Dr. Stude
    Bochum, Nordrhein-Westfalen 44787, Germany
  • Praxis Astrid Gendolla
    Essen, Nordrhein-Westfalen 45133, Germany
  • Universitätsklinikum Essen
    Essen, Nordrhein-Westfalen 45147, Germany
  • Synexus - Leipzig
    Leipzig, Sachsen 04103, Germany
  • Synexus Clinical Research - Berlin
    Berlin, 12627, Germany
  • Neuropraxis München Süd
    Unterhaching, 82008, Germany
  • Valeomed Diagnosztikai Kozpont
    Esztergom, Komarom-Esztergom County 2500, Hungary
  • Pest Megyei Flor Ferenc Korhaz
    Kistarcsa, Pest 2143, Hungary
  • UNO Medical Trials Kft.
    Budapest, 1152, Hungary
  • Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) - San Raffaele Pisana
    Rome, Roma 00163, Italy
  • Universita Campus Bio-Medico di Roma
    Roma, Rome 00128, Italy
  • Azienda Ospedaliera - Universitaria Sant' Andrea
    Roma, Rome 00189, Italy
  • IRCCS Istituto Delle Scienze Neurologiche di Bologna
    Bologna, 40139, Italy
  • Azienda Ospedaliero - Universitaria Careggi
    Florence, 50139, Italy
  • Fondazione Mondino - Istituto Neurologico Nazionale a Carattere Scientifico IRCCS
    Pavia, 27100, Italy
  • Centrum Medyczne Oporow
    Wroclaw, Dolnoslaskie 52-416, Poland
  • Centrum Medyczne Pratia - Bydgoszcz
    Bydgoszcz, Kujawsko-pomorskie 85-796, Poland
  • Prywatny Gabinet Lekarski Urszula Chyrchel-Paszkiewicz
    Lublin, Lubelskie 20-093, Poland
  • Indywidualna Praktyka Lekarska dr hab. n. med. Anna Szczepanska-Szerej
    Lublin, Lubelskie 20-582, Poland
  • Pratia MCM Krakow
    Krakow, Malopolskie 30-510, Poland
  • Specjalistyczne Gabinety Sp. z o.o.
    Krakow, Malopolskie 30-539, Poland
  • Instytut Zdrowia dr Boczarska-Jedynak
    Oswiecim, Malopolskie 32-600, Poland
  • Concept Medica Trials Prywatny Gabinet Lekarski Urszula Chyrchel-Paszkiewicz
    Warszawa, Mazowieckie 00-773, Poland
  • SOMED CR - Warsaw
    Warszawa, Mazowieckie 01-737, Poland
  • MTZ Clinical Research Powered by Pratia
    Warszawa, Mazowieckie 01-868, Poland
  • Synexus - Gdynia
    Gdynia, Pomorskie 81-537, Poland
  • Neuro-Care Katowice
    Siemianowice Slaskie, Silesia 41-100, Poland
  • Synexus - Czestochowa
    Czestochowa, Slaskie 42-202, Poland

Showing the first 100 of 138 sites across 17 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Ashina M, Lanteri-Minet M, Pozo-Rosich P, Ettrup A, Christoffersen CL, Josiassen MK, Phul R, Sperling B. Safety and efficacy of eptinezumab for migraine prevention in patients with two-to-four previous preventive treatment failures (DELIVER): a multi-arm, randomised, double-blind, placebo-controlled, phase 3b trial. Lancet Neurol. 2022 Jul;21(7):597-607. doi: 10.1016/S1474-4422(22)00185-5. PubMed 35716692 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2020 to primary completion in Jul 2021, 13 months.

Results were first posted in Jul 2022, 1 year after primary completion.

Of 114 industry-sponsored phase 3 interventional studies under Migraine Disorders, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 31. This study's 13 months is below that.

Counting every sponsor, half of 140 studies reached it within 19 months; a quarter within 12 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 3, 2020
First posted
Jun 5, 2020
StartActual
Jun 1, 2020
Primary completionActual
Jul 15, 2021
CompletionActual
Sep 15, 2022
Results first posted
Jul 22, 2022
Last update
Sep 29, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 29, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04418765
Lead sponsor
H. Lundbeck A/S
Responsible party
Sponsor
First posted
Jun 5, 2020
Start date
Jun 1, 2020
Primary completion
Jul 15, 2021
Completion
Sep 15, 2022
Results posted
Jul 22, 2022
Last update
Sep 29, 2023

Study contacts

Email contact via H. Lundbeck A/S
study director · LundbeckClinicalTrials@Lundbeck.com

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Eptinezumab

Start the discussion